anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: TERIPARATIDE
Trial phase: Phase 3
ATC code: H05AA02
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 199
Group description: Teriparatide 20 micrograms per day
Eligibility criteria:
Inclusion Criteria:

Men with primary or hypogonadal osteoporosis or postmenopausal women with osteoporosis in the opinion of the investigator. Subjects must be at high risk for fracture in the opinion of the investigator.
Willing to be trained and use the pen-injector daily to the satisfaction of study site personnel.
Able to read, understand, and respond to self-administered questionnaires.
Without language barrier, cooperative, and expected to return for all follow-up procedures.

Have provided written informed consent to participate in this study, according to local regulations after being informed of the risks, medications, and procedures to be used in the study.

Exclusion Criteria:

Any disease of sufficient severity to preclude treatment with teriparatide or participation in and completion of the study as defined by the investigator.
Having laboratory values, such as elevated serum calcium, precluding teriparatide treatment as defined by the investigator.
Subjects who have an increased baseline risk of osteosarcoma, including those with: Paget's disease of the bone or unexplained elevations of alkaline phosphatase, children and young adults with open epiphyses, and subjects who have received external beam or implant radiation therapy involving the skeleton.
History of malignant neoplasms in the 5 years prior to study entry, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated, or history of carcinoma in situ of the cervix or uterus.
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 26
Group description: 1) One group will receive the rectus sheath block prior to Umbilical hernia repair.
Eligibility criteria:
Inclusion Criteria:

Male or female subjects ages > 5 to < 18 years.
American Society of Anesthesiology (ASA)physical status 1 or 2.
Patients who undergo an umbilical hernia repair at CHOP.

Exclusion Criteria:

Parents/patients refusal to the placement of a rectus sheath nerve block.
Subjects with allergy to bupivacaine.
Patients who are developmentally delayed which precludes their participation in pain scale reporting.
Parents who do not comprehend English sufficiently well to read the consent and ask questions.
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 26
Group description: 2) The second group will receive local anesthetic infiltration of the surgical site at the end the umbilical hernia repair.
Eligibility criteria:
Inclusion Criteria:

Male or female subjects ages > 5 to < 18 years.
American Society of Anesthesiology (ASA)physical status 1 or 2.
Patients who undergo an umbilical hernia repair at CHOP.

Exclusion Criteria:

Parents/patients refusal to the placement of a rectus sheath nerve block.
Subjects with allergy to bupivacaine.
Patients who are developmentally delayed which precludes their participation in pain scale reporting.
Parents who do not comprehend English sufficiently well to read the consent and ask questions.
Intervention: Ethanol
Trial phase: Phase 4
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: subject randomized to 10ml of dehydrated alcohol
Eligibility criteria:
Inclusion Criteria:

A total of 20 consecutive subjects with locally advanced or unresectable pancreatic adenocarcinoma (stage II to IV) with pain (abdominal and/or back). Subjects with known or suspected unresectable pancreatic adenocarcinoma will be recruited for this study, as a diagnosis of unresectable pancreatic adenocarcinoma is often made during the endoscopic ultrasound (EUS) procedure.
Subjects must have documented disease by computed tomography (CT), endoscopic retrograde cholangio-pancreatography (ERCP), or EUS.
Subjects undergoing EUS for pancreatic cancer staging.
Subjects undergoing pancreatic cancer surgery are eligible for study entry beginning 5 days after the operation if they have not had an intraoperative celiac plexus neurolysis.
No evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol.

Subjects must not have a coagulopathy (platelet <50,000, INR>1.5, or bleeding disorder, or on blood thinners) Subjects with platelets below 50,000 will not be eligible to participate in this study due to the risk of bleeding. Patients will be asked to discontinue use of non-steroidals for 5 days prior to the procedure. Patients on plavix will be asked to discontinue use for 7 days prior to the procedure if they are clinically able to do so. Patients on coumadin or lovenox will also need to discontinue use prior to the procedure, but decisions regarding their management will be made on an individual basis as per our usual standards of care.

Subjects must provide signed written informed consent.
A baseline pain score is not required, however, subjects must be having pain that is requiring a stable dose of pain medication for control of pain.

Exclusion Criteria:

Subjects will be excluded if they have undergone a celiac plexus neurolysis (endoscopic, percutaneous, or surgical).
Presence of an implanted epidural or intrathecal analgesic therapy. Subjects with psychiatric illness that affects their ability to assess quality of life or compliance with the protocol.
Subjects with uncorrectable coagulopathy
Subjects with an allergy to bupivacaine or alcohol.
Presence of an aneurysm in the abdominal aorta, celiac trunk, or superior mesenteric artery.
Intervention: Ethanol
Trial phase: Phase 4
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: subject randomized to 20ml of dehydrated alcohol
Eligibility criteria:
Inclusion Criteria:

A total of 20 consecutive subjects with locally advanced or unresectable pancreatic adenocarcinoma (stage II to IV) with pain (abdominal and/or back). Subjects with known or suspected unresectable pancreatic adenocarcinoma will be recruited for this study, as a diagnosis of unresectable pancreatic adenocarcinoma is often made during the endoscopic ultrasound (EUS) procedure.
Subjects must have documented disease by computed tomography (CT), endoscopic retrograde cholangio-pancreatography (ERCP), or EUS.
Subjects undergoing EUS for pancreatic cancer staging.
Subjects undergoing pancreatic cancer surgery are eligible for study entry beginning 5 days after the operation if they have not had an intraoperative celiac plexus neurolysis.
No evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol.

Subjects must not have a coagulopathy (platelet <50,000, INR>1.5, or bleeding disorder, or on blood thinners) Subjects with platelets below 50,000 will not be eligible to participate in this study due to the risk of bleeding. Patients will be asked to discontinue use of non-steroidals for 5 days prior to the procedure. Patients on plavix will be asked to discontinue use for 7 days prior to the procedure if they are clinically able to do so. Patients on coumadin or lovenox will also need to discontinue use prior to the procedure, but decisions regarding their management will be made on an individual basis as per our usual standards of care.

Subjects must provide signed written informed consent.
A baseline pain score is not required, however, subjects must be having pain that is requiring a stable dose of pain medication for control of pain.

Exclusion Criteria:

Subjects will be excluded if they have undergone a celiac plexus neurolysis (endoscopic, percutaneous, or surgical).
Presence of an implanted epidural or intrathecal analgesic therapy. Subjects with psychiatric illness that affects their ability to assess quality of life or compliance with the protocol.
Subjects with uncorrectable coagulopathy
Subjects with an allergy to bupivacaine or alcohol.
Presence of an aneurysm in the abdominal aorta, celiac trunk, or superior mesenteric artery.
Intervention: Olopatadine Hydrochloride
Trial phase: Phase 3
SMILES: CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21.Cl
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 298
Group description: Olopatadine HCl 0.6% 1 spray per nostril twice daily
Eligibility criteria:
Inclusion Criteria:

Male or female; minimum of 6 years of age and less than 12 years
2 year history of seasonal allergic rhinitis

Exclusion Criteria:

Concurrent disease that might interfere with the investigation or evaluation of te study medication
Confirmed diagnosis of chronic rhinosinusitis within the last year
Asthma, with the exception of mild intermittent asthma
Anatomical nasal deformity
Nasal obstruction
Known non-responder to antihistamines for symptoms of Seasonal Allergic Rhinitis (SAR)
Chronic or intermittent use of of inhaled, oral, intramuscular intravenous corticosteroids ot topical steroids
Ocular disorder other that allergic conjunctivitis
Intervention: Olopatadine Hydrochloride
Trial phase: Phase 3
SMILES: CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21.Cl
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 296
Group description: Olopatadine HCl 0.6% 2 Sprays per nostril twice daily
Eligibility criteria:
Inclusion Criteria:

Male or female; minimum of 6 years of age and less than 12 years
2 year history of seasonal allergic rhinitis

Exclusion Criteria:

Concurrent disease that might interfere with the investigation or evaluation of te study medication
Confirmed diagnosis of chronic rhinosinusitis within the last year
Asthma, with the exception of mild intermittent asthma
Anatomical nasal deformity
Nasal obstruction
Known non-responder to antihistamines for symptoms of Seasonal Allergic Rhinitis (SAR)
Chronic or intermittent use of of inhaled, oral, intramuscular intravenous corticosteroids ot topical steroids
Ocular disorder other that allergic conjunctivitis
Intervention: Tiotropium
Trial phase: Phase 4
ATC code: R03AL06 | R03AL10 | R03BB04 | R03BB54
SMILES: [H][C@]1(OC(=O)C(O)(c2cccs2)c2cccs2)C[C@@]2([H])[C@]3([H])O[C@]3([H])[C@@]([H])(C1)[N+]2(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 36
Group description: Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
Eligibility criteria:
Chronic obstructive pulmonary disease (COPD) participants-

Inclusion criteria:

Body Mass Index (BMI) <36
Moderate to severe COPD patient, (similar to or slightly better than Gold Guidelines Stage 2-3, forced expiratory volume in one second [FEV_1] <60% of age predicted)
Smoking history of 10 pack years or more
Clinical diagnosis of COPD
Not on daytime oxygen

Exclusion criteria:

Clinical diagnosis of asthma
Myocardial infarction within the last 6 months, or known ischemia
Serious uncontrolled cardiac arrhythmia (i.e., atrial fibrillation or ventricular tachycardia) or hospitalization for heart failure within the previous year
Known moderate to severe renal impairment
Known moderate to severe symptomatic prostatic hypertrophy or bladder neck obstruction
Known narrow angle glaucoma
Current radiation or chemotherapy for a malignant condition
Inability to give informed consent
On systemic corticosteroids at unstable doses or on regular daily doses of 20 mg or more of prednisone (or equivalent)
Not fully recovered from an exacerbation of COPD for at least 30 days
Inability to perform light to moderate activity for orthopedic reasons or who significantly desaturated with exercise (percentage of available hemoglobin that is saturated with oxygen [SaO_2] < 85% on screening test

Healthy controls -

Inclusion:

- Age and gender matched to COPD participants

Exclusion:

- Subjects who are unable to engage in exercise testing due to existing comorbidities
Intervention: Atorvastatin
Trial phase: Phase 4
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 62
Group description: Lipitor (atorvastatin) 80 mg tablet taken once daily by mouth for 90 days
Eligibility criteria:
Inclusion Criteria:

Patients > or = to 18 years of age
Clinically indicated left atrial ablation procedure for atrial fibrillation

Exclusion Criteria:

Known malignancy
Known inflammatory disease
Surgery or trauma or myocardial infarction in the previous month
Known contraindication to statin therapy
Elevated liver enzymes above two times the upper limit of normal
Patients already receiving therapy with any statin, niacin or fibrates at the time of their randomization
Intervention: Lovaza
Trial phase: Not Applicable
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 33
Group description: 4g Lovaza (omega-3 fatty acid) daily.

omega-3 fatty acid: 4g of omega-3 fatty acid daily by mouth for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

BMI 27-45 kg/m2
age 35-65 years
abnormal carbohydrate metabolism

Exclusion Criteria:

triglycerides over 700 mg/dl
renal disease
liver disease
congestive heart failure
history of heart disease or stroke
chronic aspirin or NSAID use (anti-coagulant)
history of a bleeding disorder
use of statins, fibrates, ACE inhibitors, angiotensin II receptor blockers and glucocorticoids
diet heavy in omega-3 fatty acids (salmon, sardines, flaxseeds)
Intervention: Progesterone
Trial phase: Not Applicable
ATC code: G03DA04 | G03FA04
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](C(C)=O)CC[C@@]21[H]
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 174
Group description: Intramuscular Progesterone

Intramuscular Progesterone: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
Eligibility criteria:
Inclusion Criteria:

Singleton pregnancies
History of spontaneous preterm brith (between 20 weeks and 36 weeks 6 days)
Gestational age between 16 weeks 0 days and 20 weeks 6 days.
Signed consent to participate in the trial

Exclusion Criteria:

Multiple Gestation
Prior elective fetal reduction or planned termination
Known spontaneous reduction to singleton
Major fetal anomaly or known fetal chromosomal abnormalities
Progesteone used this pregnancy
Intervention: Progesterone
Trial phase: Not Applicable
ATC code: G03DA04 | G03FA04
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](C(C)=O)CC[C@@]21[H]
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 174
Group description: Vaginal Progesterone

Vaginal Progesterone: Vaginal Progesterone: 100 mg vaginal suppository daily
Eligibility criteria:
Inclusion Criteria:

Singleton pregnancies
History of spontaneous preterm brith (between 20 weeks and 36 weeks 6 days)
Gestational age between 16 weeks 0 days and 20 weeks 6 days.
Signed consent to participate in the trial

Exclusion Criteria:

Multiple Gestation
Prior elective fetal reduction or planned termination
Known spontaneous reduction to singleton
Major fetal anomaly or known fetal chromosomal abnormalities
Progesteone used this pregnancy
Intervention: Letrozole
Trial phase: Phase 2
ATC code: L02BG04
SMILES: N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Letrozole, 2.5 mg daily for 6 months

Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
Eligibility criteria:
Inclusion Criteria:

Post-menopausal women at high risk for development of breast cancer
stable dose of hormone replacement therapy
have cytomorphologic evidence of hyperplasia +/- atypia and Ki-67 expression >1.5% in benign breast epithelial cells acquired by RPFNA
Serum level of 25-hydroxyvitamin D of at least 30 ng/ml prior to study entry
Willing to have a repeat random periareolar fine needle aspiration (RPFNA) and mammogram at 6 months and 12 months (if participating in the open label portion of the study) following initiation of study drug

Exclusion Criteria:

Prior history of osteoporosis or osteoporotic fracture.
Prior history of invasive breast cancer or other invasive cancer within five years from date of study entry.
Current and chronic use of cyclooxygenase-2 (COX-2) specific inhibitors or NSAIDs
Receiving treatment for rheumatoid arthritis or fibromyalgia
Current history of poorly controlled migraines or perimenopausal symptoms
Currently receiving other investigational agents.
Receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane, letrozole, etc.) at any time in the past.
Intervention: Acetylcysteine
Trial phase: Not Applicable
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 41
Group description: Oral N-acetylcysteine 600 mg
Eligibility criteria:
Inclusion Criteria: 19 years of age

Baseline serum creatinine or
Calculated creatinine
Stable Renal Function
Left Ventricular ejection fraction
Non-pregnant, non-lactating females (all women of childbearing potential must have a negative serum pregnancy test. No contraception will be required
Able to sign informed consent

Exclusion Criteria:

Acute renal failure
History of Kidney transplant

Currently receiving N-acetylcysteine

_ Contraindication of hypersensitivity to N-acetylcysteine or sodium bicarbonate

Left ventricular ejection fraction
Pregnant, lactating females
Allergy to contrast dye
Intervention: Clonidine
Trial phase: Not Applicable
ATC code: C02AC01 | C02LC01 | C02LC51 | N02CX02 | S01EA04
SMILES: Clc1cccc(Cl)c1NC1=NCCN1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 9
Group description: clonidine : 3-5 microgram per kilogram every 6 hours for 10 days
Eligibility criteria:
Inclusion Criteria:

Pain not controled by morphine
Anxiety not controled by lorazepam
Burn injuries of 20% or greater
Burn type: scald or flame

Exclusion Criteria:

Small burn injury
Electrical burns
Intervention: Oxymorphone
Trial phase: Not Applicable
ATC code: N02AA11
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(C)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: oral oxymorphone ER as the basal opioid during the first 24 hours and supplemental IV-PCA oxymorphone as needed during period 1. During period 2, participants underwent a 2-week oral titration. The oxymorphone ER and IR dosages were adjusted up or down as needed to maintain pain control.
Eligibility criteria:
Inclusion Criteria:

Age of 18 to no upper limit
Chronic pain of nociceptive, neuropathic, or mixed origin
Patients with chronic non cancer pain
Ongoing chronic opioid treatment with either oral morphine or oxycodone (long term - more than 3 months of at least a total daily opioid dose of 60 mg morphine or of 30 mg oxycodone)
Pain of moderate intensity (>4, on the numerical scale 0-10) despite ongoing opioid therapy>
Non-pregnant, non-lactating women
Sufficient language skills to communicate with research staff

Exclusion Criteria:Non-ambulatory patients

Clinically significant respiratory, renal, hepatic, or cardiac disease.
Documented diagnosis of sleep apnea (the study physician may exclude patients who present with clinical features and complaints suggestive of a diagnosis of probable sleep apnea)
History of illicit drug or alcohol dependence or abuse, abnormal drug taking / seeking behaviors
Severe depression (> 26 on the BDI)
Patients who exhibit a score on the Mini Mental Status Exam (MMSE) of 26 or less. (The range of scores for mild dementia is 21-26 on the MMSE).
Workman compensation, current or pending medical-legal litigation
Hypersensitivity to study medication (oxymorphone)
Intervention: Trimethaphan
Trial phase: Not Applicable
ATC code: C02BA01
SMILES: O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 56
Group description: Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp

Blocked: Trimethaphan 4 mg/min IV will be infused for the duration of the study.

L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
Eligibility criteria:
Inclusion Criteria:

For lean subjects:
21 subjects aged 18-60 yr.
All potential volunteers will have routine blood test to screen for hepatic, renal, and hematological abnormalities.
Body mass index < 25Kg/m^2 .
Female volunteers of childbearing potential will undergo HCG pregnancy test at screening and again on the study day.
For Obese subjects with metabolic syndrome:
21 subjects aged 18-60 yr.
All potential volunteers will have routine blood test to screen for hepatic, renal, and hematological abnormalities.
Body mass index > 30Kg/m^2.

Participants will be enrolled if they met at least three of the following criteria for metabolic syndrome (Expert panel, Jama 2001):

Waist circumference >102 cm in men and >88 cm in women
High fasting blood sugar (>110 mg%)
Triglyceride levels >150 mg%
Low HDL cholesterol (<40 mg% for men; <50 mg% for women)
High blood pressure (systolic=130 and diastolic = 85 mmHg) • Female volunteers of childbearing potential will undergo serum HCG pregnancy test at screening and urine HCG pregnancy test again on the study day.

Exclusion Criteria:

Pregnant females
Subjects unable to give voluntary informed consent
Subjects on anticoagulant drugs or anemic (anemia defined as Hcto less than 35%)
Subjects with a recent medical illness documented by physicians's visit or detected during the screening visit.
Subjects with a history of coronary heart disease.
Subjects with known kidney or liver disease.
Subjects with recent weight loss or consuming low carbohydrate diet.